Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

Faculty Opinions recommendation of Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718169730.793489517 ◽

2014 ◽

Author(s):

Cesar Picado ◽

Luis Perez-de-Llano

Keyword(s):

Monoclonal Antibody ◽

Severe Asthma ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Subgroup Analysis Of A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Of Tralokinumab, An Anti-IL-13 Monoclonal Antibody, In Moderate To Severe Asthma

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2759 ◽

2012 ◽

Cited By ~ 1

Author(s):

Edward Piper ◽

Dewei She ◽

Nestor A. Molfino

Keyword(s):

Monoclonal Antibody ◽

Severe Asthma ◽

Subgroup Analysis ◽

Controlled Study ◽

Double Blind ◽

A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD)

10.26226/morressier.5b7578695aff7400151f3258 ◽

2018 ◽

Cited By ~ 1

Author(s):

Anthony Traboulsee

Keyword(s):

Monoclonal Antibody ◽

Neuromyelitis Optica ◽

Spectrum Disorder ◽

Controlled Study ◽

Neuromyelitis Optica Spectrum Disorder ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Safety and Efficacy of Monoclonal Antibody VIS410 in Adults with Uncomplicated Influenza A Infection: Results from a Randomised, Double-Blind, Placebo-Controlled Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271424 ◽

2018 ◽

Author(s):

Ellie Hershberger ◽

Susan Sloan ◽

Kristin Narayan ◽

Catherine A. Hay ◽

Patrick Smith ◽

...

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study

British Journal of Clinical Pharmacology ◽

10.1111/bcp.13748 ◽

2018 ◽

Vol 85 (2) ◽

pp. 304-315 ◽

Cited By ~ 13

Author(s):

Joanne Ellis ◽

Andre Maurik ◽

Lea Fortunato ◽

Sophie Gisbert ◽

Keguan Chen ◽

...

Keyword(s):

Monoclonal Antibody ◽

Healthy Subjects ◽

Controlled Study ◽

Double Blind ◽

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Nebulized dehydroepiandrosterone-3-sulfate improves asthma control in the moderate-to-severe asthma results of a 6-week, randomized, double-blind, placebo-controlled study

Allergy and Asthma Proceedings ◽

10.2500/aap.2010.31.3384 ◽

2010 ◽

Vol 31 (6) ◽

pp. 461-471 ◽

Cited By ~ 26

Author(s):

Sally E. Wenzel ◽

Cynthia B. Robinson ◽

Joanne M. Leonard ◽

Reynold A. Panettieri

Keyword(s):

Asthma Control ◽

Severe Asthma ◽

Controlled Study ◽

Double Blind ◽

A randomized, double-blind, placebo-controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.1780380812 ◽

1995 ◽

Vol 38 (8) ◽

pp. 1097-1106 ◽

Cited By ~ 99

Author(s):

Peter A. Van Der Lubbe ◽

Ben A. C. Dijkmans ◽

Hendrik M. Markusse ◽

Ulla Nässander ◽

Ferdinand C. Breedveld

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Early Rheumatoid Arthritis ◽

Antibody Therapy ◽

Controlled Study ◽

Monoclonal Antibody Therapy ◽

Double Blind ◽

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

Arthritis & Rheumatism ◽

10.1002/art.10623 ◽

2002 ◽

Vol 46 (12) ◽

pp. 3143-3150 ◽

Cited By ~ 356

Author(s):

E. H. S. Choy ◽

D. A. Isenberg ◽

T. Garrood ◽

S. Farrow ◽

Y. Ioannou ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Dose Escalation ◽

Interleukin 6 ◽

Therapeutic Benefit ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 6 Receptor ◽